Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.37 |
| ▸ | IDE | P14735 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL246096 | 1.00 | CDC7 (0.44) | CDC7MAPTNPSR1RECQLTDP1 | |
| SCHEMBL8513536 | 0.96 | CDC7 (0.45) | CDC7MAPTNPSR1RECQLTDP1 | |
| SCHEMBL247678 | 0.96 | CDC7 (0.45) | CDC7MAPTNPSR1RECQLTDP1 | |
| SCHEMBL246304 | 0.93 | DYRK3 (0.42) | CDC7MAPTNPSR1RECQLMEN1 | |
| SCHEMBL8510193 | 0.93 | DYRK3 (0.42) | CDC7MAPTNPSR1RECQLMEN1 | |
| SCHEMBL8512920 | 0.90 | SOS1 (0.38) | CDC7MAPTNPSR1RECQLMEN1 | |
| SCHEMBL247690 | 0.90 | SOS1 (0.38) | CDC7MAPTNPSR1RECQLMEN1 | |
| SCHEMBL252658 | 0.89 | MAPT (0.40) | CDC7MAPTNPSR1RECQLTDP1 | |
| SCHEMBL252659 | 0.89 | MAPT (0.40) | CDC7MAPTNPSR1RECQLTDP1 | |
| SCHEMBL250167 | 0.89 | DYRK3 (0.43) | CDC7MAPTNPSR1RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CRYSTALGENOMICS, INC. (KR) | 2012-05-31 | — | — | US | claimed |
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CRYSTALGENOMICS, INC. (KR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CDC7, CDCA2, CDC5L | CDC7 1/4885MAPT 4131/4885NPSR1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.